← Eichor
Study identifier: NCT07257640 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia

Condition: Hematologic Diseases · Neoplasms  ·  Sponsor: Zhejiang University

PhasePhase 1
Planned participants20
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is an open-label, single-arm clinical study designed to evaluate the efficacy and safety of IL-5 CAR-T cell therapy in the treatment of patients with CD125-positive eosinophilic leukemia.

This description comes directly from the study's public registry record.

Talk to the study team

Songmin Ying, MD  ·  0571-88208002  ·  yings@zju.edu.cn

Yongxian Hu, MD  ·  057187233772  ·  huyongxian2000@aliyun.com

Always discuss trial participation with your own doctor first.

Locations (1)

The first affiliated hospital of medical college of zhejiang universityHangzhou, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07257640